• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p21 激活激酶 4 通过磷酸化 NCoR1 抑制脂肪酸 β-氧化和酮体生成。

p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.

机构信息

Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, 54896, Republic of Korea.

School of Pharmacy, Jeonbuk National University, Jeonju, 54896, Republic of Korea.

出版信息

Nat Commun. 2023 Aug 17;14(1):4987. doi: 10.1038/s41467-023-40597-z.

DOI:10.1038/s41467-023-40597-z
PMID:37591884
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10435519/
Abstract

PPARα corepressor NCoR1 is a key regulator of fatty acid β-oxidation and ketogenesis. However, its regulatory mechanism is largely unknown. Here, we report that oncoprotein p21-activated kinase 4 (PAK4) is an NCoR1 kinase. Specifically, PAK4 phosphorylates NCoR1 at T1619/T2124, resulting in an increase in its nuclear localization and interaction with PPARα, thereby repressing the transcriptional activity of PPARα. We observe impaired ketogenesis and increases in PAK4 protein and NCoR1 phosphorylation levels in liver tissues of high fat diet-fed mice, NAFLD patients, and hepatocellular carcinoma patients. Forced overexpression of PAK4 in mice represses ketogenesis and thereby increases hepatic fat accumulation, whereas genetic ablation or pharmacological inhibition of PAK4 exhibites an opposite phenotype. Interestingly, PAK4 protein levels are significantly suppressed by fasting, largely through either cAMP/PKA- or Sirt1-mediated ubiquitination and proteasome degradation. In this way, our findings provide evidence for a PAK4-NCoR1/PPARα signaling pathway that regulates fatty acid β-oxidation and ketogenesis.

摘要

过氧化物酶体增殖物激活受体α辅抑制因子 NCoR1 是脂肪酸β氧化和酮体生成的关键调节因子。然而,其调节机制在很大程度上尚不清楚。在这里,我们报告癌蛋白 p21 激活激酶 4(PAK4)是 NCoR1 的一种激酶。具体而言,PAK4 磷酸化 NCoR1 的 T1619/T2124,导致其核定位增加,并与 PPARα相互作用,从而抑制 PPARα 的转录活性。我们观察到高脂饮食喂养的小鼠、非酒精性脂肪性肝病患者和肝细胞癌患者的肝脏组织中酮体生成减少,PAK4 蛋白和 NCoR1 磷酸化水平升高。在小鼠中强制过表达 PAK4 会抑制酮体生成,从而增加肝脂肪堆积,而 PAK4 的基因缺失或药理学抑制则表现出相反的表型。有趣的是,禁食可显著抑制 PAK4 蛋白水平,主要通过 cAMP/PKA 或 Sirt1 介导的泛素化和蛋白酶体降解。通过这种方式,我们的研究结果为调节脂肪酸β氧化和酮体生成的 PAK4-NCoR1/PPARα 信号通路提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/ea6a2517a591/41467_2023_40597_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/781deb3e8234/41467_2023_40597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/d1ab0a7bca73/41467_2023_40597_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/5bf66495a3e5/41467_2023_40597_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/78f13e4e66f3/41467_2023_40597_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/f975e5de433b/41467_2023_40597_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/cbcfcabf7cbb/41467_2023_40597_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/ea6a2517a591/41467_2023_40597_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/781deb3e8234/41467_2023_40597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/d1ab0a7bca73/41467_2023_40597_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/5bf66495a3e5/41467_2023_40597_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/78f13e4e66f3/41467_2023_40597_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/f975e5de433b/41467_2023_40597_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/cbcfcabf7cbb/41467_2023_40597_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa3/10435519/ea6a2517a591/41467_2023_40597_Fig7_HTML.jpg

相似文献

1
p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.p21 激活激酶 4 通过磷酸化 NCoR1 抑制脂肪酸 β-氧化和酮体生成。
Nat Commun. 2023 Aug 17;14(1):4987. doi: 10.1038/s41467-023-40597-z.
2
Phosphorylation of the nuclear receptor corepressor 1 by protein kinase B switches its corepressor targets in the liver in mice.蛋白激酶B对核受体辅抑制因子1的磷酸化作用改变了其在小鼠肝脏中的辅抑制因子作用靶点。
Hepatology. 2015 Nov;62(5):1606-18. doi: 10.1002/hep.27907. Epub 2015 Jul 22.
3
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.NCOR1 升高会破坏前列腺癌中的 PPARalpha/gamma 信号转导,并形成可靶向的表观遗传病变。
Carcinogenesis. 2010 Sep;31(9):1650-60. doi: 10.1093/carcin/bgq086. Epub 2010 May 13.
4
Chaperone-mediated autophagy dysregulation during aging impairs hepatic fatty acid oxidation via accumulation of NCoR1.衰老过程中伴侣介导的自噬失调通过 NCoR1 的积累损害肝脏脂肪酸氧化。
Mol Metab. 2023 Oct;76:101784. doi: 10.1016/j.molmet.2023.101784. Epub 2023 Jul 29.
5
p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.p21 激活激酶 4 通过磷酸化 FABP4 和 HSL 来拮抗 PKA 依赖性脂解。
Nat Metab. 2024 Jan;6(1):94-112. doi: 10.1038/s42255-023-00957-x. Epub 2024 Jan 12.
6
PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.PARP1介导的PPARα多聚(ADP - 核糖基)化抑制非酒精性脂肪性肝病中的脂肪酸氧化。
J Hepatol. 2017 May;66(5):962-977. doi: 10.1016/j.jhep.2016.11.020. Epub 2016 Dec 12.
7
CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway.CDKN2A/p16INK4a 通过 AMPKα2-SIRT1-PPARα 信号通路抑制肝内脂肪酸氧化。
J Biol Chem. 2020 Dec 11;295(50):17310-17322. doi: 10.1074/jbc.RA120.012543. Epub 2020 Oct 9.
8
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing.mTORC1 调控饥饿诱导的酮体生成及其被衰老调控。
Nature. 2010 Dec 23;468(7327):1100-4. doi: 10.1038/nature09584.
9
The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.过氧化物酶体增殖物激活受体β/δ 激动剂 GW501516 可防止高脂肪饮食引起的肝脏中 AMPK 的下调,并放大 PGC-1α-脂肪酶 1-PPARα 通路,导致脂肪酸氧化增加。
Endocrinology. 2011 May;152(5):1848-59. doi: 10.1210/en.2010-1468. Epub 2011 Mar 1.
10
Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice.PPARα 缺陷型新生小鼠肝糖异生和酮体生成受损。
Am J Physiol Endocrinol Metab. 2014 Jul 15;307(2):E176-85. doi: 10.1152/ajpendo.00087.2014. Epub 2014 May 27.

引用本文的文献

1
Cystathionine γ-lyase downregulation promotes liver injury and necroptosis through reprogramming of methionine cycle.胱硫醚γ-裂解酶的下调通过甲硫氨酸循环的重编程促进肝损伤和坏死性凋亡。
Redox Rep. 2025 Dec;30(1):2531650. doi: 10.1080/13510002.2025.2531650. Epub 2025 Jul 28.
2
Dietary Polyunsaturated Fatty Acid Deficiency Impairs Renal Lipid Metabolism and Adaptive Response to Proteinuria in Murine Renal Tubules.膳食多不饱和脂肪酸缺乏会损害小鼠肾小管中的肾脂质代谢及对蛋白尿的适应性反应。
Nutrients. 2025 Mar 10;17(6):961. doi: 10.3390/nu17060961.
3
p21-Activated Kinase 4 and Ischemic Acute Kidney Injury in Mice and Humans.

本文引用的文献

1
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1.p21 激活激酶 4 通过减少 α-突触核蛋白的单体和聚集形式来控制 α-突触核蛋白的聚集:E3 泛素连接酶 NEDD4-1 的参与。
Cell Death Dis. 2022 Jun 30;13(6):575. doi: 10.1038/s41419-022-05030-1.
2
Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis.Hmgcs2 介导的酮体生成调节高脂肪饮食诱导的肝脂肪变性。
Mol Metab. 2022 Jul;61:101494. doi: 10.1016/j.molmet.2022.101494. Epub 2022 Apr 12.
3
p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
p21激活激酶4与小鼠和人类的缺血性急性肾损伤
J Am Soc Nephrol. 2025 Feb 28;36(7):1264-77. doi: 10.1681/ASN.0000000649.
4
PAK4 promotes the cytoskeletal organization and meiotic maturation via phosphorylating DDX17 in oocyte.PAK4通过磷酸化卵母细胞中的DDX17来促进细胞骨架组织和减数分裂成熟。
Cell Commun Signal. 2025 Feb 13;23(1):85. doi: 10.1186/s12964-025-02085-3.
5
PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients.PAK4 参与骨肉瘤中 PD-L1 的稳定和对多柔比星的耐药性,并预测诊断患者的生存情况。
Cells. 2024 Aug 28;13(17):1444. doi: 10.3390/cells13171444.
6
PAK4 phosphorylates and inhibits AMPKα to control glucose uptake.PAK4 磷酸化并抑制 AMPKα 以控制葡萄糖摄取。
Nat Commun. 2024 Aug 10;15(1):6858. doi: 10.1038/s41467-024-51240-w.
7
p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.p21 激活激酶 4 通过磷酸化 FABP4 和 HSL 来拮抗 PKA 依赖性脂解。
Nat Metab. 2024 Jan;6(1):94-112. doi: 10.1038/s42255-023-00957-x. Epub 2024 Jan 12.
p21 激活激酶 4 抑制可预防肝缺血/再灌注损伤:核因子红细胞 2 相关因子 2 磷酸化的作用。
Hepatology. 2022 Aug;76(2):345-356. doi: 10.1002/hep.32384. Epub 2022 Apr 22.
4
Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP.甲状腺激素信号通过转录因子 ChREBP 促进肝内脂质生成。
Sci Signal. 2021 Nov 16;14(709):eabh3839. doi: 10.1126/scisignal.abh3839.
5
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease.酮体在健康和疾病中的代谢和信号作用。
Annu Rev Nutr. 2021 Oct 11;41:49-77. doi: 10.1146/annurev-nutr-111120-111518.
6
p21-activated kinase 4 phosphorylates peroxisome proliferator-activated receptor Υ and suppresses skeletal muscle regeneration.p21 激活激酶 4 磷酸化过氧化物酶体增殖物激活受体 Υ 并抑制骨骼肌再生。
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1776-1788. doi: 10.1002/jcsm.12774. Epub 2021 Aug 24.
7
mTORC1 activation is not sufficient to suppress hepatic PPARα signaling or ketogenesis.mTORC1 的激活不足以抑制肝 PPARα 信号或酮体生成。
J Biol Chem. 2021 Jul;297(1):100884. doi: 10.1016/j.jbc.2021.100884. Epub 2021 Jun 17.
8
Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway.类流星蛋白通过激活 cAMP/PKA/SIRT1 通路减轻阿霉素诱导的心脏毒性。
Redox Biol. 2020 Oct;37:101747. doi: 10.1016/j.redox.2020.101747. Epub 2020 Oct 7.
9
Systemic analysis of the expression and prognostic significance of PAKs in breast cancer.系统性分析 PAKs 在乳腺癌中的表达及预后意义。
Genomics. 2020 May;112(3):2433-2444. doi: 10.1016/j.ygeno.2020.01.016. Epub 2020 Jan 24.
10
Dysregulation of Ketone Body Metabolism Is Associated With Poor Prognosis for Clear Cell Renal Cell Carcinoma Patients.酮体代谢失调与肾透明细胞癌患者的不良预后相关。
Front Oncol. 2019 Dec 17;9:1422. doi: 10.3389/fonc.2019.01422. eCollection 2019.